Exagen Diagnostics, Inc. is a commercial-stage diagnostics company committed to addressing the significant unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases/autoimmune connective tissue disease, or ARDs/CTD.

from http://www.exagen.com

Publications show all

Exagen Diagnostics has published 12 articles.

Patents show all

36Applications14Issued

SEC Filings show all

D24S-11

SEC Form D Funding Events

DateOfferedSoldType
2015-04-01$4,547,811$1,818,767Debt
2014-07-21$3,950,000$3,950,000Debt, Security to be Acquired
2013-10-15$5,016,977$5,016,977Equity
2012-11-01$679,407$123,745Equity
2012-09-11$5,306,834$5,306,834Equity
2011-12-22$24,709,488$11,986,707Equity
2011-11-18$1,000,000$1,000,000Debt
2011-09-27$6,450,000$4,910,423Equity, Debt
2011-06-29$5,799,998$4,910,490Equity, Option to Acquire
2011-05-11$5,427,984$5,427,984Equity, Debt, Option to Acquire
2009-05-26$2,000,000$1,000,000Equity, Option to Acquire
2008-07-24UnknownUnknownOther (Paper Filing)

Key Executives

  • John P. Alsobrook, II
    Executive Officer
  • Dinesh Patel
    Director
  • John Bessone
    Director
  • Todd Stevens
    Director
  • Brian Birk
    Director
  • Lisa Davis
    Executive Officer
  • Waneta C. Tuttle
    Director
  • Scott L. Glenn
    Executive Officer, Director
  • Wendy Swedick
    Executive Officer
  • Stephanie Spong
    Director
  • Michael J. Walsh
    Director
  • Thierry Dervieux
    Executive Officer
  • Curtis LaBelle
    Director
  • David Blivin
    Director
  • David Bilvin
    Director
  • Scott Glenn
    Director
  • Ron Rocca
    Executive Officer
  • Sam Riccitelli
    Director
  • Fortunato R. Rocca
    Executive Officer, Director
  • Curt LaBelle
    Director
  • Beto Pallares
    Director
  • Michael Walsh
    Director
  • Arthur Weinstein
    Director
  • John M. Radak
    Director
  • Frank Witney
    Director